Schrödinger to Participate in Upcoming Investor Conferences

February 20, 2024

Contacts

Schrödinger (Nasdaq:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the following conferences in March:

  • TD Cowen 44th Annual Health Care Conference: Fireside chat on Tuesday, March 5, 2024 at 10:30 a.m. ET.

  • Leerink Partners Global Biopharma Conference: Fireside chat on Monday, March 11, 2024 at 12:40 p.m. E.T.

  • KeyBanc Life Sciences & MedTech Forum (Virtual): Fireside chat on Wednesday, March 20, 2024 at 10:30 a.m. E.T.

The live discussions can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.